Hyper-Personalized Medicine Market Report 2026

Hyper-Personalized Medicine Market Overview

• Hyper-Personalized Medicine market size has reached to $3188.03 billion in 2025 • Expected to grow to $6276.26 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: Surge In Precision Therapies Fueling The Growth Of The Market Due To Enhanced Targeting Of Genetic And Molecular Disease Features • Market Trend: Next-Generation Solutions For Fast And Accurate Genomic Analysis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hyper-Personalized Medicine Market?

Hyper-personalized medicine refers to an advanced healthcare approach that customizes medical treatments and interventions based on an individual’s unique genetic, molecular, environmental, and lifestyle factors. It also enhances disease prediction, accelerates drug development, minimizes trial-and-error prescribing, and improves patient outcomes through precise, targeted therapies. The main product types of hyper-personalized medicine are hyper-personalized medicine diagnostics, hyper-personalized medicine therapeutics, hyper-personalized medical care, and hyper-personalized nutrition and wellness. Hyper-personalized medicine diagnostics use detailed genetic, molecular, and lifestyle data to deliver highly tailored and precise disease detection and treatment recommendations for individual patients. They utilize various technologies such as genomics, proteomics, bioinformatics, and metabolomics and are applied in different areas, including oncology, neurology, blood transfusion safety, diabetes, autoimmune diseases, and cardiology. The key end users are hospitals, diagnostic centers, and research and academic institutes.

What Is The Hyper-Personalized Medicine Market Growth Forecast?

The hyper-personalized medicine market size is expected to see rapid growth in the next few years. It will grow to $6276.26 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to advancements in gene and cell therapies, integration of ai and bioinformatics in clinical practice, expansion of precision nutrition and wellness services, rising government initiatives supporting personalized medicine, increasing adoption of companion diagnostics and liquid biopsy technologies. Major trends in the forecast period include expansion of ai-driven clinical decision support systems, growing adoption of personalized treatment plans and precision surgery, rising demand for telemedicine and remote patient monitoring, increasing focus on nutrigenomics and personalized diet plans, development of rna-based and targeted therapeutics.

Global Hyper-Personalized Medicine Market Segmentation

1) By Product: Hyper Personalized Medicine Diagnostics, Hyper Personalized Medicine Therapeutics, Hyper Personalized Medical Care, Hyper Personalized Nutrition And Wellness 2) By Technology: Genomics, Proteomics, Bioinformatics, Metabolomics 3) By Application: Oncology, Neurology, Blood Transfusion Safety, Diabetes, Autoimmune Diseases, Cardiology 4) By End User: Hospitals, Diagnostic Centers, Research And Academic Institutes Subsegments: 1) By Hyper Personalized Medicine Diagnostics: Genomic Sequencing, Biomarker Testing, Molecular Diagnostics, Companion Diagnostics, Liquid Biopsy 2) By Hyper Personalized Medicine Therapeutics: Targeted Drug Therapies, Gene Therapy, Cell Therapy, Immunotherapy, RNA-based Therapeutics 3) By Hyper Personalized Medical Care: Telemedicine And Remote Monitoring, Personalized Treatment Plans, AI-driven Clinical Decision Support, Patient-specific Rehabilitation, Precision Surgery 4) By Hyper Personalized Nutrition And Wellness: Nutrigenomics, Personalized Diet Plans, Microbiome Analysis, Customized Supplements, Wellness Coaching And Monitoring

What Is The Driver Of The Hyper-Personalized Medicine Market?

The rising demand for precision therapies is expected to propel the growth of the hyper-personalized medicine market going forward. Precision therapies refer to medical treatments designed to target specific genetic, molecular, or cellular features of a disease, enabling more effective and personalized interventions with fewer side effects compared to traditional therapies. Precision therapies are rising due to their ability to target specific genetic or molecular features of diseases, leading to more effective and personalized treatment outcomes. Hyper-personalized medicine helps precision therapies by enabling treatments to be tailored to an individual’s unique genetic, molecular, and lifestyle factors, thereby maximizing effectiveness and minimizing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to 6 in 2022. Therefore, the rising demand for precision therapies is driving the growth of the hyper-personalized medicine industry.

Key Players In The Global Hyper-Personalized Medicine Market

Major companies operating in the hyper-personalized medicine market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Danaher Corporation, Amgen Inc., Merck KGaA, GE Healthcare Technologies Inc., Biogen Inc., Illumina Inc., Guardant Health Inc., Berry Genomics Co. Ltd., Sophia Genetics SA, Mapmygenome, InnoCare Pharma.

Global Hyper-Personalized Medicine Market Trends and Insights

Major companies in the hyper-personalized medicine market are increasingly focusing on innovative solutions, particularly accelerated whole-genome sequencing (WGS) analysis platforms, to meet growing demand for faster, more accurate genomic insights, AI-driven clinical decision support, and scalable companion diagnostics that enable truly individualized therapies and dosing. Accelerated whole-genome sequencing (WGS) analysis platforms are advanced, software-driven systems that rapidly process raw genomic data into clinically meaningful insights, helping clinicians and researchers make faster and more precise diagnostic and treatment decisions. For instance, in May 2024, SOPHiA GENETICS SA, a Switzerland-based data-driven healthcare and diagnostics company, launched a new WGS application designed to deliver fully analyzed whole-genome insights on an accelerated timeline for clinicians and researchers. The platform features end-to-end automated workflows, from raw FASTQ files through variant interpretation, while leveraging cloud computing and optimized algorithms to shorten turnaround times. It also incorporates clinical decision-support modules for oncology and rare diseases, supports scalability for hospitals and biotech organizations, and provides same-day analyzed reports in many cases.

What Are Latest Mergers And Acquisitions In The Hyper-Personalized Medicine Market?

In November 2023, Viome Life Sciences Inc., a US-based biotechnology company, acquired Naring Health Inc. for an undisclosed amount. With this acquisition, Viome aims to accelerate the development of advanced personalized nutrition solutions by integrating multi-omics data and cutting-edge research, ultimately empowering individuals to prevent and reverse chronic diseases through tailored, science-backed health insights. This strategic move strengthens Viome’s position as a leader in precision health, expanding its ability to deliver comprehensive and actionable wellness tools to a broader audience. Naring Health Inc. is a US-based provider of hyper-personalized health and nutrition solutions.

Regional Insights

North America was the largest region in the hyper-personalized medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hyper-Personalized Medicine Market?

The hyper-personalized medicine market consists of revenues earned by entities providing services such as genomic sequencing, AI-driven diagnostics, biomarker analysis, and real-time health monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyper-personalized medicine market also includes sales of genetic testing kits, portable genome sequencers, wearable health trackers, and digital pill dispensers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hyper-Personalized Medicine Market Report 2026?

The hyper-personalized medicine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hyper-personalized medicine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.